Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)

Trial Profile

A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs PU H71 (Primary) ; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Samus Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Jun 2018 According to a Samus Therapeutics media release, first patient has been dosed in this trial.
    • 26 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top